Media contacts

We welcome requests for further information or interviews.

Contact Details

Tel
+44 (0)1865 405560

Address

Northbrook House
Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA
United Kingdom

Contacts

FTI Consulting, Public Relations Adviser to Circassia

Ben Atwell / Simon Conway / Mo Noonan

Tel
+44 (0) 20 3727 1000

About Circassia

Circassia is a world-class specialty respiratory pharmaceutical business with a strong commercial infrastructure, marketed products and portfolio of treatments targeting major market opportunities. The Company sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners.  Circassia recently established a collaboration with AstraZeneca in the United States in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza®, and has the US commercial rights to the late-stage COPD product Duaklir®*.

Circassia’s broad-based development pipeline includes a range of respiratory medicines. The Company’s lead asthma treatment targets substitution of GSK’s Flixotide® pMDI and was approved in the UK.  Circassia is also developing a direct substitute for Seretide® pMDI.  In addition, the Company’s pipeline includes a number of inhaled medicines for COPD, including single and combination dose products.

*The Duaklir® trademark is registered in the United States; the mark is not currently approved for use by the FDA.